Durable Responses of Botensilimab/Balstilimab Combination in Nine Different Treatment-Resistant Cancers announced November 23, 2022
New Patient Enrollment in Ph 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas paused after patient death October 26, 2022
Results Of IDMC Review Of 12 Week Safety Data From ENVASARC Ph 2 Pivotal Trial announced – Trial To Proceed As Planned October 12, 2022
